title: Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.
abstract: BACKGROUND
  The introduction of combination antiretroviral therapy and protease inhibitors has led to reports of falling mortality rates among people infected with HIV-1. We examined the change in these mortality rates of HIV-1-infected patients across Europe during 1994-98, and assessed the extent to which changes can be explained by the use of new therapeutic regimens.
  
  
  METHODS
  We analysed data from EuroSIDA, which is a prospective, observational, European, multicentre cohort of 4270 HIV-1-infected patients. We compared death rates in each 6 month period from September, 1994, to March, 1998.
  
  
  RESULTS
  By March, 1998, 1215 patients had died. The mortality rate from March to September, 1995, was 23.3 deaths per 100 person-years of follow-up (95% CI 20.6-26.0), and fell to 4.1 per 100 person-years of follow-up (2.3-5.9) between September, 1997, and March, 1998. From March to September, 1997, the death rate was 65.4 per 100 person-years of follow-up for those on no treatment, 7.5 per 100 person-years of follow-up for patients on dual therapy, and 3.4 per 100 person-years of follow-up for patients on triple-combination therapy. Compared with patients who were followed up from September, 1994, to March, 1995, patients seen between September, 1997, and March, 1998, had a relative hazard of death of 0.16 (0.08-0.32), which rose to 0.90 (0.50-1.64) after adjustment for treatment.
  
  
  CONCLUSIONS
  Death rates across Europe among patients infected with HIV-1 have been falling since September, 1995, and at the beginning of 1998 were less than a fifth of their previous level. A large proportion of the reduction in mortality could be explained by new treatments or combinations of treatments.
authors.affiliation: Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, University College London, UK. amanda@rfhsm.ac.uk
authors.forename: A
authors.initials: A
authors.lastname: Mocroft
authors.forename: S
authors.initials: S
authors.lastname: Vella
authors.forename: T L
authors.initials: TL
authors.lastname: Benfield
authors.forename: A
authors.initials: A
authors.lastname: Chiesi
authors.forename: V
authors.initials: V
authors.lastname: Miller
authors.forename: P
authors.initials: P
authors.lastname: Gargalianos
authors.forename: A
authors.initials: A
authors.lastname: d'Arminio Monforte
authors.forename: I
authors.initials: I
authors.lastname: Yust
authors.forename: J N
authors.initials: JN
authors.lastname: Bruun
authors.forename: A N
authors.initials: AN
authors.lastname: Phillips
authors.forename: J D
authors.initials: JD
authors.lastname: Lundgren
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D015331:Cohort Studies; D003431:Cross-Cultural Comparison; D005060:Europe / Q000453:epidemiology; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000401:mortality*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D015497:HIV-1; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016019:Survival Analysis
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors